Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
LEPR Agonist REGN4461 for Familial Partial Lipodystrophy
Recruiting0 awardsPhase 2
Dallas, Texas
This trial tests REGN4461, a medication for managing high blood sugar and fat levels, in patients with low to moderate leptin levels. The treatment aims to improve how the body processes these substances, possibly reducing liver fat and hunger.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service